JP2021532833A - 細胞および/または組織の輸送用組成物および/または凍結保存用組成物 - Google Patents
細胞および/または組織の輸送用組成物および/または凍結保存用組成物 Download PDFInfo
- Publication number
- JP2021532833A JP2021532833A JP2021529495A JP2021529495A JP2021532833A JP 2021532833 A JP2021532833 A JP 2021532833A JP 2021529495 A JP2021529495 A JP 2021529495A JP 2021529495 A JP2021529495 A JP 2021529495A JP 2021532833 A JP2021532833 A JP 2021532833A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- composition according
- ion
- cryopreservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 242
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 127
- 210000001912 transporting cell Anatomy 0.000 title claims description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 141
- 210000001519 tissue Anatomy 0.000 claims abstract description 95
- 210000000056 organ Anatomy 0.000 claims abstract description 91
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 54
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims abstract description 42
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims abstract description 42
- 235000007625 naringenin Nutrition 0.000 claims abstract description 42
- 229940117954 naringenin Drugs 0.000 claims abstract description 42
- 239000007853 buffer solution Substances 0.000 claims abstract description 20
- 210000002700 urine Anatomy 0.000 claims abstract description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 122
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 claims description 22
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 20
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 19
- 108010044940 alanylglutamine Proteins 0.000 claims description 19
- 239000006177 biological buffer Substances 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 16
- 229960002648 alanylglutamine Drugs 0.000 claims description 16
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 14
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 14
- 229910001424 calcium ion Inorganic materials 0.000 claims description 14
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 14
- 229910001414 potassium ion Inorganic materials 0.000 claims description 14
- 229910001415 sodium ion Inorganic materials 0.000 claims description 14
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 229940119744 dextran 40 Drugs 0.000 claims description 13
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 13
- 239000005720 sucrose Substances 0.000 claims description 13
- 102000004877 Insulin Human genes 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 12
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 12
- 102000004338 Transferrin Human genes 0.000 claims description 12
- 108090000901 Transferrin Proteins 0.000 claims description 12
- 229940125396 insulin Drugs 0.000 claims description 12
- 239000012581 transferrin Substances 0.000 claims description 12
- 229930182555 Penicillin Natural products 0.000 claims description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 10
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 10
- 229940049954 penicillin Drugs 0.000 claims description 10
- 229960001471 sodium selenite Drugs 0.000 claims description 10
- 239000011781 sodium selenite Substances 0.000 claims description 10
- 235000015921 sodium selenite Nutrition 0.000 claims description 10
- 229960005322 streptomycin Drugs 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 35
- 210000002510 keratinocyte Anatomy 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229960001031 glucose Drugs 0.000 description 16
- 239000002577 cryoprotective agent Substances 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 230000035899 viability Effects 0.000 description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000001934 delay Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 229910052711 selenium Inorganic materials 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 229940091258 selenium supplement Drugs 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 238000003349 alamar blue assay Methods 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000006163 transport media Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229940091250 magnesium supplement Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000004687 hexahydrates Chemical class 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 150000002207 flavanone derivatives Chemical class 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000004918 root sheath Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229940082569 selenite Drugs 0.000 description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010583 slow cooling Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- PYQVCYCHUWIDIS-UHFFFAOYSA-N 2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-6-ol Chemical compound OC1=C(C)C(C)=C2OC(C)CCC2=C1C PYQVCYCHUWIDIS-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000006029 phytogenic feed additive Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
- C12N5/0628—Hair stem cells; Hair progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
Abstract
Description
本出願は、2018年7月30日に出願された「細胞および/または組織の輸送用組成物および/または凍結保存用組成物」という名称の米国仮特許出願第62/711,808号の優先権を主張するものであり、この出願の内容は参照によりその全体が本明細書に援用される。
この実施例では、細胞、組織および臓器を輸送するための本発明の一態様による輸送用組成物の好ましい処方について述べる。
a.485mM NaCl、
b.40mM KCl、
c.0.6mM CaCl2、
d.5mM MgCl2六水和物、
e.60mM Na2CO3、
f.120mM Na2HPO4、
g.230mM HEPES、
h.110mM D−(+)−グルコースおよび
i.20mM Ala−Gln
を含む。
a.48.5mM NaCl、
b.4mM KCl、
c.0.06mM CaCl2、
d.0.5mM MgCl2六水和物、
e.6mM Na2CO3、
f.12mM Na2HPO4、
g.23mM HEPES、
h.11mM D−(+)−グルコース、
i.2mM Ala−Gln、
j.0.05μM ナリンゲニン、
k.0.1μM トロロックス[(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸]および
l.0.0005%(v/v)DMSO(ナリンゲニンとトロロックスに使用した溶媒;最終濃度は0.0005%(v/v)を超えないこと)
を含む。
以下の実施例では、細胞、組織および臓器を凍結保存するための本発明の一態様による凍結保存用組成物の好ましい処方について述べる。
a.485mM NaCl、
b.40mM KCl、
c.0.6mM CaCl2、
d.5mM MgCl2六水和物、
e.60mM Na2CO3、
f.120mM Na2HPO4、
g.230mM HEPES、
h.110mM D−(+)−グルコースおよび
i.20mM Ala−Gln
を含む。
本出願の目的に関して、「X、YおよびZのうちの少なくとも1つ」または「1つ以上のX、YおよびZ」という用語は、Xのみ、Yのみ、Zのみ、またはX、YおよびZのうちの2つ以上の任意の組み合わせ(例えば、XYZ、XYY、YZ、ZZ)を指す。
Claims (34)
- a.ナリンゲニン、
b.緩衝系および
c.糖成分
を含む、細胞、組織または臓器の輸送用組成物。 - ナリンゲニンの濃度が約0.01μM〜約10μMである、請求項1に記載の組成物。
- ナリンゲニンの濃度が約0.01μM〜約0.25μMである、請求項1に記載の組成物。
- 前記緩衝系が、
a.約15mM〜約45mMの合成生物学的緩衝液、
b.約2mM〜約20mMの重炭酸水素塩、
c.約6mM〜約25mMのリン酸水素塩、または
これらの組み合わせ
を含む、請求項1〜3のいずれか1項に記載の組成物。 - 前記緩衝系が、
a.約15mM〜約45mMの合成生物学的緩衝液、
b.約3mM〜約9mMの重炭酸水素塩、
c.約10mM〜約15mMのリン酸水素塩、または
これらの組み合わせ
を含む、請求項1〜3のいずれか1項に記載の組成物。 - 前記糖成分が、約2mM〜約25mMのD−グルコースを含む、請求項1〜5のいずれか1項に記載の組成物。
- 前記糖成分が、約9mM〜約15mMのD−グルコースを含む、請求項1〜5のいずれか1項に記載の組成物。
- a.約20mM〜約120mMのナトリウムイオン、
b.約0.01mM〜約1mMのカルシウムイオン、
c.約10mM〜約70mMの塩化物イオン、
d.約2mM〜約12mMのカリウムイオン、
e.約0.1mM〜約1mMのマグネシウムイオン、
f.約0.2mM〜約10mMのアラニルグルタミン、
g.約0.01μM〜約10μMの(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸、または
これらの組み合わせ
をさらに含む、請求項1〜7のいずれか1項に記載の組成物。 - a.約70mM〜約90mMのナトリウムイオン、
b.約0.03mM〜約1mMのカルシウムイオン、
c.約40mM〜約60mMの塩化物イオン、
d.約2mM〜約5mMのカリウムイオン、
e.約0.4mM〜約0.7mMのマグネシウムイオン、
f.約1mM〜約5mMのアラニルグルタミン、
g.約0.05μM〜約0.25μMの(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸、または
これらの組み合わせ
をさらに含む、請求項1〜7のいずれか1項に記載の組成物。 - a.約0.1μg/mL〜約20μg/mLのインスリン、
b.約1μg/mL〜約20μg/mLのトランスフェリン、
c.約5nM〜約50nMの亜セレン酸ナトリウム、または
これらの組み合わせ
をさらに含む、請求項1〜9のいずれか1項に記載の組成物。 - a.約8μg/mL〜約12μg/mLのインスリン、
b.約3μg/mL〜約7μg/mLのトランスフェリン、
c.約20nM〜約40nMの亜セレン酸ナトリウム、または
これらの組み合わせ
をさらに含む、請求項1〜9のいずれか1項に記載の組成物。 - a.約10単位/mL〜約200単位/mLのペニシリン、
b.約0.01mg/mL〜約1mg/mLのストレプトマイシン、または
これらの組み合わせ
をさらに含む、請求項1〜11のいずれか1項に記載の組成物。 - a.約80単位/mL〜約120単位/mLのペニシリン、
b.約0.08mg/mL〜約0.2mg/mLのストレプトマイシン、または
これらの組み合わせ
をさらに含む、請求項1〜11のいずれか1項に記載の組成物。 - 前記細胞、組織または臓器が、ヒト毛包、ヒト毛包由来細胞または尿由来細胞である、請求項1〜13のいずれか1項に記載の組成物。
- 細胞、組織または臓器の輸送用組成物であって、
a.約0.01μM〜約0.25μMのナリンゲニン、
b.約15mM〜約45mMの合成生物学的緩衝液、
c.約3mM〜約9mMの重炭酸水素塩、
d.約10mM〜約15mMのリン酸水素塩、
e.約9mM〜約15mMのD−グルコース、
f.約70mM〜約90mMのナトリウムイオン、
g.約0.03mM〜約1mMのカルシウムイオン、
h.約40mM〜約60mMの塩化物イオン、
i.約2mM〜約5mMのカリウムイオン、
j.約0.4mM〜約0.7mMのマグネシウムイオン、
k.約1mM〜約5mMのアラニルグルタミン、および
l.約0.05μM〜約0.25μMの(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸
を含む、組成物。 - 前記細胞、組織または臓器を凍結保存する前に、該細胞、組織または臓器の輸送に使用される、請求項1〜15のいずれか1項に記載の組成物。
- a.ナリンゲニン、
b.緩衝系および
c.糖成分
を含む、細胞、組織または臓器の凍結保存用組成物。 - ナリンゲニンの濃度が約0.01μM〜約10μMである、請求項17に記載の組成物。
- ナリンゲニンの濃度が約0.01μM〜約0.25μMである、請求項17に記載の組成物。
- 前記緩衝系が、
a.約15mM〜約45mMの合成生物学的緩衝液、
b.約2mM〜約20mMの重炭酸水素塩、
c.約6mM〜約25mMのリン酸水素塩、または
これらの組み合わせ
を含む、請求項17〜19のいずれか1項に記載の組成物。 - 前記緩衝系が、
a.約15mM〜約45mMの合成生物学的緩衝液、
b.約3mM〜約9mMの重炭酸水素塩、
c.約10mM〜約15mMのリン酸水素塩、または
これらの組み合わせ
を含む、請求項17〜19のいずれか1項に記載の組成物。 - 前記糖成分が、約2mM〜約25mMのD−グルコースを含む、請求項17〜21のいずれか1項に記載の組成物。
- 前記糖成分が、約9mM〜約15mMのD−グルコースを含む、請求項17〜21のいずれか1項に記載の組成物。
- a.約20mM〜約120mMのナトリウムイオン、
b.約0.01mM〜約1mMのカルシウムイオン、
c.約10mM〜約70mMの塩化物イオン、
d.約2mM〜約12mMのカリウムイオン、
e.約0.1mM〜約1mMのマグネシウムイオン、
f.約0.2mM〜約10mMのアラニルグルタミン、
g.約0.01μM〜約10μMの(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸、または
これらの組み合わせ
をさらに含む、請求項17〜23のいずれか1項に記載の組成物。 - a.約70mM〜約90mMのナトリウムイオン、
b.約0.03mM〜約1mMのカルシウムイオン、
c.約40mM〜約60mMの塩化物イオン、
d.約2mM〜約5mMのカリウムイオン、
e.約0.4mM〜約0.7mMのマグネシウムイオン、
f.約1mM〜約5mMのアラニルグルタミン、
g.約0.05μM〜約0.25μMの(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸、または
これらの組み合わせ
をさらに含む、請求項17〜23のいずれか1項に記載の組成物。 - a.約0.1μg/mL〜約20μg/mLのインスリン、
b.約1μg/mL〜約20μg/mLのトランスフェリン、
c.約5nM〜約50nMの亜セレン酸ナトリウム、または
これらの組み合わせ
をさらに含む、請求項17〜25のいずれか1項に記載の組成物。 - a.約8μg/mL〜約12μg/mLのインスリン、
b.約3μg/mL〜約7μg/mLのトランスフェリン、
c.約20nM〜約40nMの亜セレン酸ナトリウム、または
これらの組み合わせ
をさらに含む、請求項17〜26のいずれか1項に記載の組成物。 - a.約10単位/mL〜約200単位/mLのペニシリン、
b.約0.01mg/mL〜約1mg/mLのストレプトマイシン、または
これらの組み合わせ
をさらに含む、請求項17〜26のいずれか1項に記載の組成物。 - a.約80単位/mL〜約120単位/mLのペニシリン、
b.約0.08mg/mL〜約0.2mg/mLのストレプトマイシン、または
これらの組み合わせ
をさらに含む、請求項17〜28のいずれか1項に記載の組成物。 - a.約0.001g/mL〜約0.2g/mLのデキストラン40、
b.約10mM〜約60mMのショ糖、
c.約0.1%(v/v)〜約20%(v/v)のジメチルスルホキシド、または
これらの組み合わせ
をさらに含む、請求項17〜29のいずれか1項に記載の組成物。 - a.約0.03g/mL〜約0.07g/mLのデキストラン40、
b.約20mM〜40mMのショ糖、
c.約2.5%(v/v)〜約10%(v/v)のジメチルスルホキシド、または
これらの組み合わせ
をさらに含む、請求項17〜29のいずれか1項に記載の組成物。 - 前記細胞、組織または臓器が、ヒト毛包、ヒト毛包由来細胞または尿由来細胞である、請求項17〜31のいずれか1項に記載の組成物。
- 細胞、組織または臓器の凍結保存用組成物であって、
a.約0.01μM〜約0.25μMのナリンゲニン、
b.約15mM〜約45mMの合成生物学的緩衝液、
c.約3mM〜約9mMの重炭酸水素塩、
d.約10mM〜約15mMのリン酸水素塩、
e.約9mM〜約15mMのD−グルコース、
f.約70mM〜約90mMのナトリウムイオン、
g.約0.03mM〜約1mMのカルシウムイオン、
h.約40mM〜約60mMの塩化物イオン、
i.約2mM〜約5mMのカリウムイオン、
j.約0.4mM〜約0.7mMのマグネシウムイオン、
k.約1mM〜約5mMのアラニルグルタミン、
l.約0.05μM〜約0.25μMの(±)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸、
m.約0.03g/mL〜約0.07g/mLのデキストラン40、
n.約20mM〜40mMのショ糖、および
o.約5%(v/v)未満のジメチルスルホキシド
を含む、組成物。 - 前記細胞、組織または臓器を輸送した後に、該細胞、組織または臓器の凍結保存に使用される、請求項17〜33のいずれか1項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862711808P | 2018-07-30 | 2018-07-30 | |
US62/711,808 | 2018-07-30 | ||
PCT/CA2019/051036 WO2020024045A1 (en) | 2018-07-30 | 2019-07-26 | Compositions for transportation and/or cryopreservation of cells and/or tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021532833A true JP2021532833A (ja) | 2021-12-02 |
Family
ID=69230425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021529495A Pending JP2021532833A (ja) | 2018-07-30 | 2019-07-26 | 細胞および/または組織の輸送用組成物および/または凍結保存用組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210289770A1 (ja) |
EP (1) | EP3829296A4 (ja) |
JP (1) | JP2021532833A (ja) |
KR (1) | KR20210052451A (ja) |
CN (1) | CN112752505A (ja) |
AU (1) | AU2019316505A1 (ja) |
BR (1) | BR112021001820A2 (ja) |
CA (1) | CA3107967A1 (ja) |
MX (1) | MX2021001205A (ja) |
WO (1) | WO2020024045A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113767895B (zh) * | 2021-09-23 | 2022-09-13 | 北京大麦植发技术研究有限公司 | 一种毛囊组织复合保存液、其制备方法以及维持毛囊离体活性的保存方法 |
CN117859736A (zh) * | 2024-03-12 | 2024-04-12 | 安宁市中医医院 | 一种用于毛囊保存的存储液及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140241A2 (en) * | 2010-05-04 | 2011-11-10 | The General Hospital Corporation | Methods and compositions for preserving tissues and organs |
JP2016111927A (ja) * | 2013-04-03 | 2016-06-23 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
WO2016159773A1 (en) * | 2015-04-03 | 2016-10-06 | Tx Innovations B.V. | Organ preservation composition |
CA3011208A1 (en) * | 2016-01-15 | 2017-07-20 | Universitat Hamburg | Methods for the production of rhamnosylated flavonoids |
CN109511650B (zh) * | 2018-11-21 | 2021-06-15 | 嘉兴莱普晟医疗科技有限公司 | 一种可以扩大供肝来源的常温机械灌注液 |
CN109511649B (zh) * | 2018-11-21 | 2021-06-25 | 嘉兴莱普晟医疗科技有限公司 | 一种可以扩大供肝来源的常温机械灌注*** |
-
2019
- 2019-07-26 AU AU2019316505A patent/AU2019316505A1/en active Pending
- 2019-07-26 WO PCT/CA2019/051036 patent/WO2020024045A1/en active Application Filing
- 2019-07-26 CA CA3107967A patent/CA3107967A1/en active Pending
- 2019-07-26 KR KR1020217005914A patent/KR20210052451A/ko active Search and Examination
- 2019-07-26 EP EP19844065.3A patent/EP3829296A4/en active Pending
- 2019-07-26 MX MX2021001205A patent/MX2021001205A/es unknown
- 2019-07-26 BR BR112021001820-4A patent/BR112021001820A2/pt unknown
- 2019-07-26 CN CN201980062818.7A patent/CN112752505A/zh active Pending
- 2019-07-26 JP JP2021529495A patent/JP2021532833A/ja active Pending
- 2019-07-26 US US17/264,602 patent/US20210289770A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3829296A4 (en) | 2022-05-04 |
US20210289770A1 (en) | 2021-09-23 |
KR20210052451A (ko) | 2021-05-10 |
EP3829296A1 (en) | 2021-06-09 |
WO2020024045A1 (en) | 2020-02-06 |
CN112752505A (zh) | 2021-05-04 |
BR112021001820A2 (pt) | 2021-04-27 |
MX2021001205A (es) | 2021-09-08 |
CA3107967A1 (en) | 2020-02-06 |
AU2019316505A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jang et al. | Cryopreservation and its clinical applications | |
US11497206B2 (en) | Cell cryopreservation protective composition and use thereof | |
EP1950283B1 (en) | Aqueous solution for cell preservation | |
CN109843052A (zh) | 用于细胞冷冻保存的组合物和方法 | |
US20200170244A1 (en) | Methods for preserving, transporting and storing living biological materials | |
CA2635968A1 (en) | Cryoprotective compositions and methods of using same | |
ES2948810T3 (es) | Método para obtener una población enriquecida de células madre mesenquimales funcionales, células así obtenidas y composiciones que las comprenden | |
JP6879949B2 (ja) | 治療目的のための細胞の凍結保存方法 | |
AU2017377309B2 (en) | Mammalian cell cryopreservation liquid | |
US9055739B2 (en) | Compositions for cryopreservation of cells | |
JP2016111927A (ja) | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 | |
JP2021532833A (ja) | 細胞および/または組織の輸送用組成物および/または凍結保存用組成物 | |
WO2013047666A1 (ja) | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 | |
CN116473051A (zh) | 一种无血清非程序细胞冻存液及其制备方法和应用 | |
WO2013047665A1 (ja) | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 | |
CN106561632A (zh) | 用于脂肪干细胞的冻存液及其制备方法以及培养基 | |
US20220354108A1 (en) | Preservation methods using trehalose with other cryoprotectants being absent from the cryopreservation protocol | |
ES2614041T3 (es) | Método de lavado celular adherentes usando solución de lavado celular que contiene trehalosa | |
EP3719115A1 (en) | Composition and method for the cultivation, expansion, preservation and/or pre-treatment of cells | |
RU2731065C1 (ru) | Состав криоконсерванта для длительного хранения первичных кератиноцитов | |
BR102017024173A2 (pt) | Solução de água de coco desidratada, processo de obtenção, e seu uso para preservação de órgãos e tecidos | |
KR20100116425A (ko) | 동물 배아의 보존 방법 | |
Wolkers et al. | 77. Effect of gamma sterilization on proteins in AlloDermTM regenerative tissue matrix | |
JP2014198673A (ja) | 動物胚の低温保存用の保存剤及び低温での動物胚の保存方法 | |
TW202043452A (zh) | 細胞冷凍保存液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210219 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230620 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240116 |